VALBY, Denmark , March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in Japan.
Oddity Tech Ltd. (NASDAQ:ODD ) Q4 2024 Earnings Conference Call February 26, 2025 8:30 AM ET Company Participants Maria Lycouris - IR Oran Holtzman - Co-Founder and CEO Niv Price - CTO Lindsay Drucker Mann - Global CFO Conference Call Participants Cory Carpenter - JPMorgan Youssef Squali - Truist Securities Javier Escalante - Evercore ISI Andrew Boone - Citizens Dara Mohsenian - Morgan Stanley Scott Schoenhaus - KeyBanc Capital Markets Lorraine Hutchinson - Bank of America Lauren Lieberman - Barclays Operator Good morning.
Oddity Tech (ODD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.17 per share a year ago.
Oddity Tech disrupts the beauty industry by leveraging AI and data to enhance online shopping, boasting high consumer satisfaction and repeat purchase rates. The company's DTC model and in-house marketing provide control over brand image and inventory, ensuring sustainable growth and high ROAS. Management's commitment to a 20% growth algorithm and integrity in pacing growth demonstrate long-term vision and strategic planning.
Oddity Tech (ODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- On January 31, 2025, ODDITY Tech Ltd. (NASDAQ: ODD, the “Company”) entered into agreements with a syndicate of banks to secure credit facilities for a total of $200 million (collectively the “Facility”). The Facility replaces the Company's previous $100 million credit facility and increases financial flexibility to fund growth initiatives, acquisitions, share buybacks, and other general corporate needs.
ODD is disrupting the legacy beauty and wellness market with technologies like AI, machine learning, data science and computer vision.
Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease
Oddity Tech's data-driven, AI-powered DTC model looks set to facilitate market share gains through FY28. ODD's forward EV/EBITDA valuation of 16.2x is pricier than the industry average, but we feel it is worth this premium, considering the superior EBITDA profile of the business. ODD's robust balance sheet, zero debt, and strong free cash flow support have prompted a shift towards share buyback momentum with another $100m yet to be deployed.
From a technical perspective, Oddity Tech (ODD) is looking like an interesting pick, as it just reached a key level of support. ODD recently overtook the 20-day moving average, and this suggests a short-term bullish trend.